Plaque Psoriasis

In this analysis presented at Maui Derm, indirect comparisons were made between risankizumab and icotrokinra in patients with psoriasis.

The Maui Derm Hawaii 2026 conference featured a poster presentation highlighting recent phase 3 findings on risankizumab in pediatric patients.

The safety and efficacy of risankizumab versus deucravacitinib were evaluated among patients with moderate psoriasis and no prior biologic use.

This Q&A interview with Dawn Eichenfield, MD, PhD, highlights notable takeaways from her session at Maui Derm Hawaii titled ‘Pediatric Dermatology 2026.’

This interview at the 2026 Maui Derm Hawaii meeting features a discussion of new and emerging therapies in psoriasis, including icotrokinra.

At the 2026 Maui Derm Hawaii meeting, recent data on icotrokinra’s use in patients with psoriasis were highlighted.

This survey highlights several key findings related to patient concerns and caregiver concerns over topical steroids (TCS).

This analysis suggests TYK2 (tyrosine kinase 2) inhibitors may have a dual therapeutic potential to address both skin symptoms of psoriasis and comorbid depressive symptoms.

In her interview, Melinda Gooderham, MD, highlights the impact of recent topline findings on zasocitinib, a once-daily pill for adults with psoriasis.

In this post hoc analysis, investigators used phase 3 data on vunakizumab to investigate the impact of early response on long-term efficacy in those with psoriasis.

This study evaluated the drug survival of different biologic therapies for patients with psoriasis in a routine clinical practice setting.

This study highlights the efficacy and safety of deucravacitinib 6 mg in psoriasis, with results stratified by body mass index and age in a Japanese patient cohort.

Two phase 3 trials met their primary and secondary endpoints in patients with moderate-to-severe plaque psoriasis on envudeucitinib.

This quarterly recap highlights some of the most notable news and developments in the dermatology space from Q4 in 2025.

Investigators conducted a network meta-analysis comparing and ranking the safety and efficacy of dietary supplements as adjunctive therapy for patients with psoriasis.

Investigators explored the measurement properties of the Patient-Reported Outcomes Measurement Information System (PROMIS) among patients with chronic skin disease.

Catch up on news headlines highlighted in the dermatology space by HCPLive in 2025 with this Year in Review.

Catch up on some of the most notable headlines in psoriasis news coverage from 2025 with our Year in Review.

In this analysis, investigators assessed the effects of any weight-loss intervention, behavioural or pharmacological, on the severity of psoriasis as well as quality-of-life outcomes.

Topical steroid withdrawal remains a controversial topic in the dermatology field, given the lack of necessary data.

The highly selective oral TYK2 inhibitor met coprimary endpoints for sPGA 0/1 and PASI 75 at week 16 versus placebo in the phase 3 Latitude studies.

Investigators highlighted patterns of addictive behavior among those with chronic skin diseases in European tertiary dermatology centers.

Vanda Pharmaceuticals submitted a BLA to the FDA for imsidolimab, a novel IgG4 IL-36 receptor antagonist, to treat generalized pustular psoriasis (GPP).

The phase 3 DISCREET study explored the safety and efficacy of apremilast in treating patients with moderate to severe genital psoriasis over 32 weeks.

From diagnosis, investigators sought to explore psoriasis characteristics, patient demographics, patterns of treatment, and disease progression.